They also observed that in 28% of patients predicted to be sensitive to treatment, 3-year distant relapse-free survival (DRFS) was 92%, with a significant absolute risk reduction of 18%.
研究者同时发现有28%的患者被预测为对治疗敏感,他们的3年无远处复发生存率为92%,绝对危险度大幅下降18%。
We report a64-year-old man previously diagnosed with limited stage small cell lung cancer that presented with painless hematuria and arf after a2-year relapse-free period.
我们报告一位六十四岁先前诊断为局限阶段小细胞肺癌的男性病人,经过两年无复发时期后,呈现出无痛性血尿和急性肾衰竭。
She achieved a complete response and remains relapse-free 21months after her last dose of chemotherapy. Conclusion.
患者获得了完全缓解并在末次化疗后的21个月持续无复发。
She achieved a complete response and remains relapse-free 21months after her last dose of chemotherapy. Conclusion.
患者获得了完全缓解并在末次化疗后的21个月持续无复发。
应用推荐